Aerin Medical
Venture Round in 2025
Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company develops therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, addressing underlying causes of conditions like nasal obstruction and chronic rhinitis. Its flagship products include the VivAer procedure and device for nasal airway obstruction, as well as the RhinAer procedure and device for chronic rhinitis. These innovative offerings enable ENT physicians to provide effective treatments in an office setting, often with local anesthesia and little to no downtime for patients, making them appealing alternatives to traditional invasive surgeries.
Sonex Health
Series B in 2023
Sonex Health is a medical device company focused on reducing invasiveness and costs in orthopedic care through micro-invasive surgical tools. Based in Rochester, Minnesota, it developed the SX-One MicroKnife with Meerkat Technology to treat carpal tunnel syndrome via Micro-invasive Carpal Tunnel Release (USCTR). The device enables a micro-incision guided by ultrasound or a small mini-open incision without ultrasound, up to five times smaller than traditional carpal tunnel release, allowing procedures in a surgery center or office setting with rapid recovery and minimal immobilization. The company aims to improve safety while lowering procedural costs and delivering effective relief of carpal tunnel symptoms.
Allotex, Inc. is an ophthalmic biologics and device company based in Boston, Massachusetts. Founded in 2013, it specializes in the development of innovative contact lenses and therapeutic solutions aimed at addressing refractive vision issues such as presbyopia, hyperopia, and myopia. Allotex utilizes precisely-shaped human corneal allografts in conjunction with a compact excimer laser system to create permanent, living contact lenses or lens inserts. This approach allows medical professionals to provide the least invasive treatment options for various refractive procedures, enhancing patient outcomes in vision correction.
Candesant Biomedical
Series B in 2023
Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.
Revamp Medical
Series A in 2023
Revamp Medical, founded in 2016, is dedicated to addressing the critical unmet needs of patients suffering from acute heart failure. With over one million annual admissions in the United States and associated costs exceeding $65 billion, the company aims to provide an innovative solution through its patented temporary catheter, Doraya™. This device regulates vascular hemodynamics, particularly for patients experiencing diuretic resistance, by managing preload and reducing central venous pressure. This functionality enhances diuretic efficacy and facilitates progressive decongestion, thereby allowing cardiologists to effectively manage key hemodynamic parameters. Revamp Medical is supported by a skilled team with extensive experience in the medical technology sector, positioning the company to make a significant impact in the treatment of acute heart failure.